Program
LW402
A development code. Also written as “Experimental LW402 Tablet” and “Drug: LW402”.
Its studies are mostly in Dermatitis, Atopic · Vitiligo · Arthritis, Rheumatoid, led by Shanghai Longwood Biopharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Longwood Biopharmaceuticals | 42 open or running | phase 3since Jan 19, 2026 | Oct 11, 2024 | Feb 1, 2028phase 2 · NCT07556471 |
Also a collaborator on its studies: tigermed-consulting-co-ltd and clinical-service-china.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2024First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT06800157 · 72 enrolled · China
- Sep 15, 2025Phase 2 study in Dermatitis, AtopicNCT07186387 · 144 enrolled · China
- Jan 19, 2026Phase 3 study in Moderate to Severe Atopic DermatitisPhase 3 reachedNCT07370909 · 480 planned · China
- Apr 16, 2026Phase 2 study in Non-Segmental Vitiligo (NSV)NCT07556471 · 180 planned
Ahead
- Feb 1, 2028Primary completion: phase 2 study in Non-Segmental Vitiligo (NSV)NCT07556471
- Mar 31, 2028Primary completion: phase 3 study in Moderate to Severe Atopic DermatitisNCT07370909
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07556471Non-Segmental Vitiligo (NSV) | 2 | Not yet recruiting | Feb 1, 2028 | 180 |
| NCT07370909Moderate to Severe Atopic Dermatitis · China | 3 | Recruiting | Mar 31, 2028 | 480 |
| NCT07186387Dermatitis, Atopic · China | 2 | Completed | Sep 25, 2024 | 144 |
| NCT06800157Arthritis, Rheumatoid · China | 2 | Completed | May 26, 2024 | 72 |
How it is read
Names in the registry
- “LW402”, 2 entries
- “Experimental LW402 Tablet”, 1 entry
- “Drug: LW402”, 1 entry
Codes read as this program: LW402.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Vitiligo, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.